ALT Altimmune Inc.

2.69
-0.05  -2%
Previous Close 2.74
Open 2.75
Price To Book 0.75
Market Cap 36196924
Shares 13,451,105
Volume 125,152
Short Ratio
Av. Daily Volume 1,863,142

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 trial met primary endpoint.
HepTCell
Hepatitis B
Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected.
NasoVAX
Flu vaccine
Phase 1 data showed limited response.
NASOSHIELD
Anthrax

Latest News

  1. Altimmune To Present NasoVAX Phase 2 Data at the World Vaccine Congress in Washington, D.C.
  2. Altimmune, Inc. to Host Earnings Call
  3. Altimmune Announces Financial Results for the Year Ended December 31, 2018 and Provides Corporate Update
  4. Altimmune to Announce Year End 2018 Financial Results on April 2
  5. Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data
  6. Altimmune's stock soars on heavy volume after positive trial data of flu vaccine candidate
  7. Altimmune Announces Positive Results from NasoVAX Extension Study
  8. Altimmune to Participate at 31st Annual ROTH Conference
  9. Altimmune Announces Closing of $14 Million Registered Direct Offering
  10. Altimmune Announces $14 million Registered Direct Offering
  11. Altimmune Announces Presentation of HepTcell Phase 1 Results at The International Liver Congress™ in Vienna, Austria
  12. Today's Research Reports on Trending Tickers: Sage Therapeutics and Altimmune
  13. Altimmune Announces Clinical Program Updates and Plans for Pipeline Expansion
  14. Altimmune Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  15. Altimmune Appoints Vipin K. Garg, Ph.D. as its New President and Chief Executive Officer
  16. Today's Research Reports on Trending Tickers: Altimmune and Johnson & Johnson
  17. Altimmune Announces Third Quarter 2018 Financial Results and Provides Corporate Update
  18. Gaithersburg biotech CEO to step down
  19. Today’s Research Reports on Stocks to Watch: Altimmune and MannKind